Company intelligence / Profile preview

Xianchuang Investment

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Xianchuang Medical is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of next-generation cell therapies for solid tumors. The company leverages its proprietary CAR-T and TCR-T technology platforms to engineer immune cells capable of overcoming the immunosuppressive microenvironment of solid cancers. Its lead candidate, XC-101, is a CAR-T therapy targeting Claudin 18.2, currently being evaluated in clinical trials for gastric and pancreatic cancers. Xianchuang Medical aims to address significant unmet medical needs in oncology through innovative cell-based immunotherapies.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on Xianchuang Investment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xianchuang Investment.

Explore the full profile